Cytotoxic and DNA-damaging properties of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and Its analogues

Biochemical Pharmacology

Volumn 56, Issue 3, 1998, Pages 351-359

  Pastwa, Elzbieta ^a   Ciesielska, Ewa ^a   Piestrzeniewicz, Mariola K ^a   Denny, William A ^b   Gniazdowski, Marek ^a   Szmigiero, Leszek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antitumor acridines; ICRF 187; Topoisomerase II inhibitors

Indexed keywords

9 AMINOACRIDINE 4 [N (2 DIMETHYLAMINOETHYL)CARBOXAMIDE]; ACRIDINE DERIVATIVE; AMSACRINE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; N [2 (HYDROXYETHYLAMINO)ETHYL] 9 AMINOACRIDINE 4 CARBOXAMIDE; N [2 (HYDROXYETHYLAMINO)ETHYL]ACRIDINE 4 CARBOXAMIDE; RAZOXANE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHROMATIN STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; LEUKEMIA L 1210; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; DNA; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; ETOPOSIDE; MICE; RAZOXANE; RNA;

EID: 0031681383     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00030-6     Document Type: Article

References (40)

1. Denny WA, Baguley BC. New anticancer acridines. Neidle S, Waring MJ. Molecular Aspects of Anticancer Drug-DNA Interaction. 1994;270-311 Macmillan, London.
2. Gniazdowski M, Szmigiero L. Nitracine and its congeners-an overview. Gen Pharmacol. 26:1995;473-481.
3. Denny WA, Atwell GJ, Rewcastle GW, Baguley BC. Potential antitumor agents. 49. 5-substituted derivatives of N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide with in vivo solid tumor activity. J Med Chem. 30:1987;658-663.
4. Atwell GJ, Rewcastle GW, Baguley BC, Denny WA. Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem. 30:1987;664-669.
5. Wakelin LPG, Atwell GJ, Rewcastle GW, Denny WA. Relationships between DNA-binding kinetics and biologic activity for the 9-aminoacridine-4-carboxamide class of antitumor agents. J Med Chem. 30:1987;855-861.
6. Bailly C, Denny WA, Mellor LE, Wakelin LPG, Waring MJ. Sequence specificity of the binding of 9-aminoacridine- and amsacrine-4-carboxamides to DNA studied by DNase I footprinting. Biochemistry. 31:1992;3514-3524.
7. Woynarowski JM, McCarthy K, Reynolds B, Beerman TA, Denny WA. Topoisomerase II-mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide. Anti-Cancer Drug Design. 9:1994;9-24.
8. Piestrzeniewicz MK, Czyz M, Denny WA, Gniazdowski M. Inhibition of RNA synthesis in vitro by 9-aminacridine carboxamide antitumor agents. Effect on overall RNA synthesis and synthesis of the initiating dinucleotide. Acta Biochim Polon. 37:1990;299-307.
9. Crenshaw JM, Graves DE, Denny WA. Interactions of acridine antitumor agents with DNA: Binding energies and groove preferences. Biochemistry. 34:1995;13682-13687.
10. Nelson EM, Tewey KM, Liu LF. Mechanism of antitumor drug action: Poisoning of mammalian topoisomerase II on DNA by 4′-(9-acridinylamino)-methansulfon-m-anisidide. Proc Natl Sci USA. 81:1984;1361-1365.
11. Wakelin LPG, Denny WA. Kinetic and equilibrium binding studies of a series of intercalating agents that bind by threading a sidechain through the DNA helix. Pullman B, Jortner J. Molecular Basis of Specificity in Nucleic Acid-Drug Interactions. 1990;191-206 Kluwer Academic Publishers, Dortrecht.
12. Jensen PB, Sorensen BS, Sehested M, Demant EJF, Kjeldsen E, Friche E, Hansen HH. Different modes of anthracycline interaction with topoisomerase II. Biochem Pharmacol. 45:1993;2025-2035.
13. Jensen PB, Sorensen BS, Sehested M, Grue P, Demant EJF, Hansen HH. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res. 54:1994;2959-2963.
14. Sehested M, Jensen PB. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol. 51:1996;879-886.
15. Gniazdowski M, Cera C. The effects of DNA covalent adducts on in vitro transcription. Chem Rev. 96:1996;619-634.
16. Wakelin LPG, Polyfunctional DNA. intercalating agents. Med Res Rev. 6:1986;275-340.
17. Cain BF, Atwell GJ, Denny WA. Potential antitumor agents. 23. 4′-(9-acridynylamino)alkanesulfonoanilidine congeners bearing hydrophilic functionality. J Med Chem. 20:1977;987-996.
18. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of tetrazolium-based semiautomtic colorimetric assay: Assessment of chemosensitivity testing. Cancer Res. 47:1987;936-942.
19. Kohn KW. Principles and practice of DNA filter elution. Pharmacol Ther. 49:1991;55-77.
20. Strniste GF, Rall SC. Induction of stable protein DNA adducts in Chinese hamster cell chromatin by ultraviolet light. Biochemistry. 15:1976;1712-1719.
21. Walicka M, Szmigiero L, Ciesielska E, Gra̧dzka I. Are lethal effects of nitracrine on L5178Y cell sublines associated with DNA-protein cross-links? Biochem Pharmacol. 46:1993;615-620.
22. Sullivan DM, Latham MD, Ross WE. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse and Chinese hamster ovary cells. Cancer Res. 47:1987;3973-3979.
23. Gniazdowski M, Czyz M, Wilmańska D, Frasunek M, Płucienniczak A, Szmigiero L. Inhibition of DNA-dependent RNA synthesis by 8-methoxypsoralen. Biochim Biophys Acta. 950:1988;346-353.
24. Ross WE, Glaubiger DL, Kohn KW. Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. Biochim Biophys Acta. 519:1978;23-30.
25. Zwelling LA, Michaels S, Erickson LC, Ungerleider RS, Nichols M, Kohn KW. Protein-associated DNA strand breaks in L1210 cells treated with the DNA intercalating agents 4′-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin. Biochemistry. 20:1981;6553-6563.
26. Muggia FM, Burris HA. Clinical development of topoisomerase-interactive drugs. Adv Pharmacol. 29B:1994;1-31.
27. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons harnessing the dark side of enzyme mechanism . J Biol Chem. 270:1995;21429-21432.
28. Harvey VJ, Hardy JR, Smith S, Grove W, Baguley BC. Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small-cell lung cancer. Eur J Cancer. 27:1991;1617-1620.
29. Baguley BC, Zhuang L, Marshall E. Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide. Cancer Chemother Pharmacol. 36:1995;244-248.
30. Finlay GJ, Marshall ES, Matthews JHL, Paull KD, Baguley BC. In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother Pharmacol. 31:1993;401-406.
31. Finlay GJ, Riou J-F, Baguley BC. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): Selectivity for topoisomerase I and II among acridine derivatives. Eur J Cancer. 32A:1996;708-714.
32. Atwell GJ, Cain BF, Baguley BC, Finlay J, Denny WA. Potential antitumor agents. 43. Synthesis and biologic activity of dibasic 9-aminoacridine-4-carboxamides, a new class antitumour agent. J Med Chem. 27:1984;1481-1485.
33. Schneider E, Darkin SJ, Lawson PA, Ching L-M, Ralph RK, Baguley BC. Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: Role of DNA topoisomerase II. Eur J Cancer Clin Oncol. 24:1988;1783-1790.
34. Wilson WR, Baguley BC, Wakelin LPG, Waring MJ. Interaction of the antitumor drug 4′-(9-acridinylamino)methanesulfon-m-anisidide and related acridines with nucleic acids. Mol Pharmacol. 20:1981;404-414.
35. Spicer JA, Gamage A, Atwell GJ, Finlay GJ, Baguley BC, Denny WA. Structure-activity relationships for acridine-substituted analogs of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem. 40:1997;1919-1929.
36. Kawada S, Yamashita Y, Fujii N, Nakano H. Induction of a heat-stable topoisomerase II-DNA complex by nonintercalative terpenoids, terpentecin and clerocidin. Cancer Res. 51:1991;2922-2925.
37. Pommier Y, Minford JK, Schwartz RE, Zwelling LA, Kohn KW. Effects of the DNA intercalators 4′-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II-mediated DNA strand cleavage and strand passage. Biochemistry. 24:1985;6410-6416.
38. Konopa J and Majcher R, Covalent DNA interstrand crosslinking in tumor cells by 9-amino-4-carboxamidoacridines. In: Proceedings of the 16th International Congress on Chemotherapy, Jerusalem, 796.1, 1989.
39. Kohn KW, Beyond DNA. cross-linking history and prospects of DNA-targeted cancer treatment-Fifteenth Bruce F. Cain Memorial Award Lecture . Cancer Res. 56:1996;5533-5546.
40. Darzynkiewicz Z, Kapuściński J. Condensation of DNA in situ in metaphase chromosomes induced by intercalating ligands and its relationship to chromosome banding. Cytometry. 9:1988;7-18.